SMAD4 inhibited the proliferation, migration, and invasion of CCA, and enhanced the sensitivity of cholangiocarcinoma to pemotinib, the only FDA-approved targeted drug for CCA by inhibiting β-catenin-S675 phosphorylation and intranuclear translocation [75]. This evidence concerns the gene SMAD4 and cholangiocarcinoma.